Blood test monitoring for early-stage breast cancer
Part of Cancer, Skin clinical trials.
This study uses a simple blood test called liquid biopsy to monitor cancer DNA in people with early-stage breast cancer before and during treatment. The goal is to see if this test can help guide treatment and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with early-stage breast cancer (stage I, II, or III)
- You are scheduled to receive chemotherapy or targeted therapy before surgery (neoadjuvant treatment)
- You must have a tumor sample available for testing
- You have not received any prior treatment for this breast cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial tests a blood test that looks for chemical changes in DNA to help diagnose breast cancer. It may offer a simpler way to detect cancer without needing a tissue sample.
This study tests a new blood test that aims to find breast cancer early in women who are at higher risk or are going for routine screening. If you are a woman aged 30–75 and are scheduled for a mammogram, MRI, or breast ultrasound, you may be able to help validate this test.
This study uses a simple blood test (liquid biopsy) along with imaging scans to look for early signs that triple-negative breast cancer may have returned in patients who still had cancer after chemo. It aims to catch a possible recurrence sooner, which could help guide earlier treatment.
This study looks at whether a simple blood test can help doctors see how well treatment is working for advanced breast cancer that has stopped responding. It may help guide future care.
This trial is testing whether a blood test can track how well chemotherapy is working in people with early-stage triple-negative breast cancer. You would provide blood samples before and during treatment, and the results may help your doctor understand your response better.
Hear when a new Early Breast Cancer (EBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.